Xiang, K, Wang, E, Mantyh, J, Rupprecht, G, Negrete, M, Sanati, G, Hsu, C, Randon, PM, Dohlman, AB, Kretzschmar, K, Bose, S, Giroux, N, Ding, S, Wang, L, Balcazar, JP, Huang, Q, Sundaramoorthy, P, Xi, R, McCall, S, Wang, Z, Jiang, C, Kang, Y, Kopetz, S , Crawford, G, Lipkin, SM, Wang, XF, Clevers, H, Hsu, D, Shen, X
This aligns well with the gradual and sustainable weight loss philosophy we advocate at Center for SmartLipo & Plastic Surgery
2016 May 24;8:108
Individuals taking a GLP-1 receptor agonist were 9.1 times more likely to experience pancreatitis, 4.2 times more likely to have a bowel obstruction, and 3.7 times more likely to have gastroparesis compared to patients taking another type of drug
That single distinctionsmall moleculeis the key to understanding why this drug is genuinely different from anything that came before it